Phase 1 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who weigh at least 60 kg (approximately 132 pounds)
- People who are willing and able to sign a consent form before any trial procedures begin
- People whose cancer has not responded to standard treatments, or for whom no proven treatments exist, or who are not eligible for established treatment options — and who have already tried at least one chemotherapy regimen containing platinum-based drugs (previous treatment with certain immune checkpoint drugs, known as anti-PD-1 or anti-PD-L1 therapies, is also allowed)
- People who are in relatively good general health and able to carry out daily activities, as measured by a standard medical scale (ECOG score of 0 or 1) (confirm with trial site)
- People who have at least one measurable area of cancer located outside the brain, as assessed using standard imaging criteria
- People who have cancer that has spread to the brain may still be eligible, provided that any brain radiation or surgery was completed at least 2 weeks before the first study treatment, they have been off steroid medications for at least 7 days (low maintenance doses may be permitted), and they have been off anti-seizure medications for at least 7 days, or have been on a stable dose of anti-seizure medication for their brain disease
- Additional eligibility criteria may apply (confirm with trial site)
Who may not be able to join:
- People who have had, or currently have, a separate cancer diagnosis within the past 2 years — with some exceptions, such as certain effectively treated skin cancers, cervical carcinoma in situ, ductal carcinoma in situ, or another cancer considered fully cured by local treatment
- People who have had a major injury, surgery, or bone fracture within 28 days before the first dose of the study drug, or who have surgery planned during the trial period
- People with cancer that has spread to the membranes surrounding the brain or spinal cord, or that is compressing the spinal cord
- People who are on blood-thinning (anticoagulant) medication that cannot safely be paused if medically necessary, based on the treating doctor's judgement
- People with an active infection currently requiring medical treatment
- People who have had a confirmed COVID-19 infection within 2 weeks before entering the study, are suspected to have COVID-19, or have had close contact with a confirmed COVID-19 case within the past week
- People with certain active hepatitis B or hepatitis C virus infections, based on specific blood test results (confirm with trial site for details)
- People with a known HIV infection
- Additional exclusion criteria may apply (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-800-243-0127
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean relative change from baseline of [89Zr]Zr-BI 764532 tumour-to-plasma ratios in all detectable lesions post BI 764532 doses
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.